Key facts
- This page summarizes Alex G. Howarth's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Jan 2024, 15:29.
Alex G. Howarth - 23 Jan 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- MDGL
- Reported as of
- 23 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jan 2024, 15:29:59 UTC
- Prior SEC filing
- 18 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian J. Lynch**
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alex G. Howarth filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 25 Jan 2024.
Change
- Previous filing in this sequence was filed on 18 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MDGL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +4,803
- Change %
- +34%
- Price
- $0.000000
- Shares after
- 18,737
- Date
- 23 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDGL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,238
- Change %
- Price
- $0.000000
- Shares after
- 7,238
- Date
- 23 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,238
- Exercise price
- $229.00
- Footnotes
- F2
MDGL
transaction
Derivative
Market Stock Unit
Award
- Transaction value
- $0
- Shares
- +4,803
- Change %
- Price
- $0.000000
- Shares after
- 4,803
- Date
- 23 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,803
- Exercise price
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
Footnote F2
The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
Footnote F3
Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.
SEC remarks
**As attorney-in-fact for Reporting Person